Streetbeat News

ALPMF

Astellas Pharma Inc.

https://www.astellas.com/jp/

CEO

Kenji Yasukawa

Industry

Medicinal and Botanical Manufacturing

Open

12.00

Mkt cap

20B

Volume

575

High

12.00

P/E Ratio

55.50

52-wk high

12.74

Low

11.10

Div yield

0.04

52-wk low

9.13

William Blair has initiated coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with an Outperform rating, highlighting the competitive edge of its drug Syfovre in the market for geographic atrophy secondary to age-related macular degeneration. Despite competition from Novartis' Fabhalta, Apellis' Empaveli has significant market opportunities in C3G and IC-MPGN. The analyst projects peak sales for Syfovre to reach $2.0 billion by 2030.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 6:57 pm

Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.

Portfolio Pulse from Vandana Singh

August 05, 2024 | 6:27 pm

Astellas Pharma and Pfizer have received FDA approval for a supplemental marketing application for Xtandi (enzalutamide) to treat nonmetastatic castration-sensitive prostate cancer with a high risk of metastasis after biochemical recurrence.

Portfolio Pulse from Benzinga Newsdesk

November 17, 2023 | 8:52 am

Merck & Co Inc announced that its Phase 3 AMBASSADOR trial evaluating Keytruda, a cancer drug, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma. The trial will continue to evaluate its other dual primary endpoint of overall survival. Other Phase 3 studies in muscle-invasive bladder cancer include the KEYNOTE-866 trial and the Phase 3 KEYNOTE-B15 and Phase 3 KEYNOTE-905 trials, which are being conducted in collaboration with Seagen Inc and Astellas Pharma Inc.

Portfolio Pulse from Vandana Singh

October 05, 2023 | 1:35 pm

Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 3:05 pm

Astellas Pharma has decided not to exercise its option to obtain an exclusive license to TSHA-120 under the Option Agreement with Taysha Gene Therapies. This decision comes after Taysha submitted a new comprehensive analysis to the FDA in June 2023, with the FDA recommending a randomized, double-blind, placebo-controlled trial as the optimal path to demonstrate efficacy in TSHA-120. Following this, Taysha's shares fell by 6.13%.

Portfolio Pulse from Vandana Singh

September 20, 2023 | 6:12 pm

The FDA has granted priority review to Pfizer and Astellas Pharma's XTANDI for non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence. This could potentially expedite the drug's approval process.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2023 | 10:47 am

Iveric Bio Inc's board of directors has approved a merger proposal with Astellas Pharma at a special meeting held on July 6.

Portfolio Pulse from Happy Mohamed

July 06, 2023 | 5:07 pm

Astellas Pharma has licensed gene therapy KT430 from Kate Therapeutics for X-linked myotubular myopathy (XLMTM), a rare muscle disorder. This follows safety issues with Astellas' AT132 gene therapy, which led to a clinical hold from the FDA. Kate Therapeutics has also raised $51 million in a Series A financing round.

Portfolio Pulse from Vandana Singh

June 08, 2023 | 4:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.